水腎症治療の世界市場2019-2023

◆英語タイトル:Global Hydronephrosis Therapies Market 2019-2023
◆商品コード:IRTNTR30113
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年11月21日
◆ページ数:116
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥374,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥535,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

水腎症とは、腎臓の内部が拡張もしくは伸長している症状であり、通常、腎臓結石用鎮痛剤や薬剤が水腎症治療薬として使われています。Technavioのアナリストは、2019年から2023年の間に、世界の水腎症治療市場が9.14%のCAGRで成長すると予測しています。

主な分析対象企業は、Allergan、F. Hoffmann-La Roche、Novartis、Pfizer、Teva Pharmaceutical Industriesなどです。

当調査レポートでは、水腎症治療の世界市場について調査・分析し、市場概要、市場環境、水腎症治療市場規模、製品別(抗生物質療法、他の療法)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。

・エグゼクティブサマリー
・調査範囲・調査手法
・水腎症治療の世界市場概要
・水腎症治療の世界市場環境
・水腎症治療の世界市場動向
・水腎症治療の世界市場規模
・水腎症治療の世界市場:業界構造分析
・水腎症治療の世界市場:製品別(抗生物質療法、他の療法)
・水腎症治療の世界市場:地域別市場規模・分析
・水腎症治療の北米市場規模・予測
・水腎症治療のヨーロッパ・中東・アフリカ市場規模・予測
・水腎症治療のアジア太平洋市場規模・予測
・水腎症治療の主要国分析
・水腎症治療の世界市場:意思決定フレームワーク
・水腎症治療の世界市場:成長要因、課題
・水腎症治療の世界市場:競争環境
・水腎症治療の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About Hydronephrosis
Hydronephrosis is a condition when the inside of the kidney gets dilated or stretched and usually analgesics and drugs for kidney stones are used as therapeutics for hydronephrosis.
Technavio’s analysts forecast the Global Hydronephrosis Therapies Market to grow at a CAGR of 9.14% during the period 2019-2023.

Covered in this report
The report covers the present scenario and the growth prospects of the hydronephrosis therapies market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of hydronephrosis across the globe.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, hydronephrosis therapies market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendor
• Allergan
• F. Hoffmann-La Roche
• Novartis
• Pfizer
• Teva Pharmaceutical Industries
Market driver
• growing prevalence of kidney diseases that result in a higher incidence of hydronephrosis
• For a full, detailed list, view our report

Market challenge
• Availability of alternate therapies
• For a full, detailed list, view our report

Market trend
• Increasing awareness of kidney diseases
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2023 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Antibiotic therapy – Market size and forecast 2018-2023
• Other therapies – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Allergan
• F. Hoffmann-La Roche
• Novartis
• Pfizer
• Teva Pharmaceutical Industries
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global urological disorder drugs market
Exhibit 02: Segments of global urological disorder drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Product – Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Antibiotic therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Antibiotic therapy – Year-over-year growth 2019-2023 (%)
Exhibit 21: Other therapies – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Other therapies – Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in Americas
Exhibit 30: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in EMEA
Exhibit 33: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in APAC
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: ALLERGAN – Vendor overview
Exhibit 47: ALLERGAN – Business segments
Exhibit 48: ALLERGAN – Organizational developments
Exhibit 49: ALLERGAN – Geographic focus
Exhibit 50: ALLERGAN – Segment focus
Exhibit 51: ALLERGAN – Key offerings
Exhibit 52: ALLERGAN: Key customers
Exhibit 53: F. Hoffmann-La Roche – Vendor overview
Exhibit 54: F. Hoffmann-La Roche – Business segments
Exhibit 55: F. Hoffmann-La Roche – Organizational developments
Exhibit 56:
Exhibit 57: F. Hoffmann-La Roche – Geographic focus
Exhibit 58: F. Hoffmann-La Roche – Segment focus
Exhibit 59: F. Hoffmann-La Roche – Key offerings
F. Hoffmann-La Roche: Key customers
Exhibit 60: Novartis – Vendor overview
Exhibit 61: Novartis – Business segments
Exhibit 62: Novartis – Organizational developments
Exhibit 63: Novartis – Geographic focus
Exhibit 64: Novartis – Segment focus
Exhibit 65: Novartis – Key offerings
Exhibit 66: Novartis – Key customers
Exhibit 67: Pfizer – Vendor overview
Exhibit 68: Pfizer – Organizational developments
Exhibit 69: Pfizer – Geographic focus
Exhibit 70: Pfizer – Segment focus
Exhibit 71: Pfizer – Key offerings
Exhibit 72: Pfizer – Key customers
Exhibit 73: Teva Pharmaceutical Industries – Vendor overview
Exhibit 74: Teva Pharmaceutical Industries – Business segments
Exhibit 75: Teva Pharmaceutical Industries – Organizational developments
Exhibit 76: Teva Pharmaceutical Industries – Geographic focus
Exhibit 77: Teva Pharmaceutical Industries – Segment focus
Exhibit 78: Teva Pharmaceutical Industries – Key offerings
Exhibit 79: Teva Pharmaceutical Industries: Key customers



【掲載企業】

Allergan、F. Hoffmann-La Roche、Novartis、Pfizer、Teva Pharmaceutical Industries

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[水腎症治療の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆